Novast is focused on the research, development and manufacture of value-added generic drugs.
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel.Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market.Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 29, 2021 | Series Unknown | ¥400M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Shiyu Ziben | — | Series Unknown |